Zhongzhi Pharmaceutical Holdings Limited (HK:3737)
:3737
Want to see HK:3737 full AI Analyst Report?
Top Page
Zhongzhi Pharmaceutical Holdings Limited
(3737)
Select Model
Select Model
Rating:57Neutral
Price Target:
HK$0.87
▼(-1.25% Downside)
Action:ReiteratedDate:04/25/26
The score is driven primarily by weakened financial performance (sharp 2025 revenue and margin deterioration) offset by a relatively conservative balance sheet and still-positive (but softer) free cash flow. Technicals are broadly neutral with a mild positive bias, while valuation is supported by a high dividend yield but constrained by a relatively high P/E for a company facing near-term earnings pressure.
Positive Factors
Conservative Balance Sheet
Low leverage and a stable equity base provide durable financial flexibility. With debt-to-equity near 0.21 the company can better withstand cyclical revenue pressure, fund targeted R&D or regulatory requirements, and pursue opportunistic investments without immediate refinancing stress.
Negative Factors
Sharp Revenue Decline
A greater-than-20% revenue drop in the latest fiscal year signals weakening demand or lost market share. Prolonged top-line contraction undermines scale economics, pressures margins and makes funding consistent R&D, commercial expansion, or dividend distributions more difficult over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage and a stable equity base provide durable financial flexibility. With debt-to-equity near 0.21 the company can better withstand cyclical revenue pressure, fund targeted R&D or regulatory requirements, and pursue opportunistic investments without immediate refinancing stress.
Read all positive factors
Zhongzhi Pharmaceutical Holdings Limited (3737) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$677.60M
Dividend Yield9.43%
Average Volume (3M)412.77K
Price to Earnings (P/E)24.6
Beta (1Y)0.05
Revenue Growth-21.54%
EPS Growth-81.79%
CountryHK
Employees2,577
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.01
Shares Outstanding863,600,000
10 Day Avg. Volume391,300
30 Day Avg. Volume412,766
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)0.38
Price to Sales (P/S)0.24
P/FCF Ratio5.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhongzhi Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Zhongzhi Pharmaceutical Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company operates through three segments: Pharmac...
Zhongzhi Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.69B | 2.21B | 2.05B | 1.83B | 1.75B |
| Gross Profit | 921.41M | 1.29B | 1.22B | 1.07B | 1.06B |
| EBITDA | 153.19M | 170.39M | 317.53M | 153.87M | 119.71M |
| Net Income | 16.84M | 95.21M | 162.78M | 106.39M | 52.13M |
Balance Sheet | |||||
| Total Assets | 1.83B | 1.99B | 1.79B | 1.88B | 1.52B |
| Cash, Cash Equivalents and Short-Term Investments | 200.89M | 167.10M | 166.65M | 419.36M | 242.18M |
| Total Debt | 227.02M | 188.60M | 225.06M | 170.86M | 175.74M |
| Total Liabilities | 732.02M | 865.58M | 739.30M | 869.31M | 622.94M |
| Stockholders Equity | 1.10B | 1.12B | 1.05B | 1.00B | 898.74M |
Cash Flow | |||||
| Free Cash Flow | 69.88M | 39.62M | -69.93M | 196.17M | -7.47M |
| Operating Cash Flow | 104.19M | 181.48M | 101.50M | 284.57M | 178.38M |
| Investing Cash Flow | -52.73M | -120.06M | -202.76M | 13.38M | -135.98M |
| Financing Cash Flow | -117.07M | -58.73M | -154.62M | -68.14M | -40.83M |
Zhongzhi Pharmaceutical Holdings Limited Technical Analysis
Positive
0.88
Price Trends
0.80
Positive
0.72
Positive
0.73
Positive
Market Momentum
0.02
Positive
53.38
Neutral
48.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3737, the sentiment is Positive. The current price of 0.88 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.80, and above the 200-day MA of 0.73, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 53.38 is Neutral, neither overbought nor oversold. The STOCH value of 48.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3737.
Zhongzhi Pharmaceutical Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$779.10M | 3.58 | 12.80% | 7.52% | -9.66% | 16.17% | |
60 Neutral | HK$659.50M | 9.74 | 5.66% | 2.92% | 2.57% | -1.27% | |
57 Neutral | HK$677.60M | 24.59 | 1.57% | 9.43% | -21.54% | -81.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$867.56M | 11.90 | -48.86% | ― | -15.98% | 93.93% | |
46 Neutral | HK$367.75M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% | |
42 Neutral | HK$157.81M | -4.22 | -30.35% | ― | -12.03% | 6.24% |
* Healthcare Sector Average
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.81
-0.05
-5.81%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.33
-0.03
-9.72%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.15
-0.15
-11.54%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.18
-37.50%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.16
0.90
346.15%
HK:0239
Pak Fah Yeow International Limited
2.50
0.41
19.62%
Zhongzhi Pharmaceutical Holdings Limited Corporate Events
Zhongzhi Pharmaceutical Sets 2026 AGM to Seek Mandates on Share Buybacks and Issuance
Apr 20, 2026
Zhongzhi Pharmaceutical Holdings Limited has called its annual general meeting for 13 May 2026 in Hong Kong, where shareholders will vote on the approval of the audited financial statements for the year ended 31 December 2025 and the re-election o...
Zhongzhi Pharmaceutical Profit Slumps 82% as Revenue Falls and Dividend Is Scrapped
Mar 26, 2026
Zhongzhi Pharmaceutical Holdings Limited reported a sharp downturn in its 2025 annual results, with revenue falling 21.6% year on year to RMB1.74 billion and gross profit dropping 26.6% to RMB945.9 million, compressing the group’s gross marg...
Zhongzhi Pharmaceutical Plans Governance Overhaul to Meet New HKEX Rules
Mar 26, 2026
Zhongzhi Pharmaceutical Holdings Limited, a Cayman-incorporated pharmaceutical group listed in Hong Kong under stock code 3737, has a board structure that includes executive, non-executive and independent non-executive directors. As a listed issue...
Zhongzhi Pharmaceutical Sets March 2026 Board Meeting to Approve 2025 Results and Potential Dividend
Mar 16, 2026
Zhongzhi Pharmaceutical Holdings Limited has scheduled a board meeting in Hong Kong on 26 March 2026 to review and approve the audited annual results for the year ended 31 December 2025. The board will also consider whether to recommend a final di...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.